Under one in 10 individuals eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the WHO as it releases its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just access to these injectable treatments.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The latest guidance recognises that excess weight is a long-term condition that can be treated with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant obstacles to universal availability to the injections that can assist patients in reducing significant body mass, notes the body.
Skinny Jab Scarcity
Even under the present best projected case, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – under 10% of eligible patients, according to the health organization.
The guideline calls on nations and manufacturers to increase availability, through measures such as licensing agreements.
A patent on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in several nations in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs mimick a natural hormone to slow digestion, reduce hunger and enhance satiety so individuals eat less.
People usually see weight reduction in the initial weeks of commencing the once-weekly jabs.
Research indicates patients may put most of the weight back on a year later of discontinuing the drug, when their normal food cravings return.
To be overweight or obese increases your likelihood for developing diseases, such as diabetes, heart disease, stroke, and some cancers.
Obesity impacts people in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
